JOURNAL ARTICLE

Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis

Juyan Zhou, Yunhua Chen, Setareh Tabibi, Luis Alba, Elizabeth Garber, Lisa Saiman

Antimicrobial Agents and Chemotherapy 2007, 51 (3): 1085-8

Susceptibility (18 antimicrobial agents including high-dose tobramycin) and checkerboard synergy (23 combinations) studies were performed for 2,621 strains of Burkholderia cepacia complex isolated from 1,257 cystic fibrosis patients. Minocycline, meropenem, and ceftazidime were the most active, inhibiting 38%, 26%, and 23% of strains, respectively. Synergy was rarely noted (range, 1% to 15% of strains per antibiotic combination).

Read this article (multiple options)

OPEN IN READ APP

PUBMED • http://www.ncbi.nlm.nih.gov/pubmed/17158942

Find additional links »

Discussion

You are not logged in. Sign Up or Log In to join the discussion.

Related Papers

Emerging cystic fibrosis pathogens: incidence and antimicrobial resistance. Annarita Magni, Alessandra Giordano, Carlo Mancini, Claudia Pecoraro, Paola Varesi, Serena Quattrucci, Maria Trancassini New Microbiologica 2007, 30 (1): 59-62

In vitro activity of doripenem (S-4661) against multidrug-resistant gram-negative bacilli isolated from patients with cystic fibrosis. Yunhua Chen, Elizabeth Garber, Qiuqu Zhao, Yigong Ge, Matthew A Wikler, Koné Kaniga, Lisa Saiman Antimicrobial Agents and Chemotherapy 2005, 49 (6): 2510-1

Burkholderia cepacia complex infection in adult patients with cystic fibrosis--is early eradication possible? C Etherington, D G Peckham, S P Conway, M Denton Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society 2003, 2 (4): 220-1

In vitro activities of antimicrobial agents, alone and in combinations, against Burkholderia cepacia isolated from blood. D C Lu, S C Chang, Y C Chen, K T Luh, W C Hsieh Diagnostic Microbiology and Infectious Disease 1997, 28 (4): 187-91

Use of breakpoint combination sensitivity testing as a simple and convenient method to evaluate the combined effects of ceftazidime and tobramycin on Pseudomonas aeruginosa and Burkholderia cepacia complex isolates in vitro. Michael M Tunney, Eileen M Scott Journal of Microbiological Methods 2004, 57 (1): 107-14

Burkholderia cepacia genomovar III and Burkholderia vietnamiensis double infection in a cystic fibrosis child. Marcelo Magalhães, Murilo C A de Britto, Peter Vandamme Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society 2002, 1 (4): 292-4

Routine susceptibility testing of four antibiotic combinations for improvement of laboratory guide to therapy of cystic fibrosis infections caused by Pseudomonas aeruginosa. K Weiss, J R Lapointe Antimicrobial Agents and Chemotherapy 1995, 39 (11): 2411-4

Clonality and Antimicrobial Susceptibility of Burkholderia cepacia complex Isolates Collected from Cystic Fibrosis Patients during 1998-2013 in Bern, Switzerland. Agnese Lupo, Enver Isis, Regula Tinguely, Andrea Endimiani New Microbiologica 2015, 38 (2): 281-8

Sputum antibiotic concentrations: implications for treatment of cystic fibrosis lung infection. T F Moriarty, J C McElnay, J S Elborn, M M Tunney Pediatric Pulmonology 2007, 42 (11): 1008-17

In vitro efficacy of high-dose tobramycin against Burkholderia cepacia complex and Stenotrophomonas maltophilia isolates from cystic fibrosis patients. Anina Ratjen, Yvonne Yau, Jillian Wettlaufer, Larissa Matukas, James E A Zlosnik, David P Speert, John J LiPuma, Elizabeth Tullis, Valerie Waters Antimicrobial Agents and Chemotherapy 2015, 59 (1): 711-3

Want full text access to this paper?

Use Read by QxMD to access full text via your institution or open access sources.

Read also provides personalized recommendations to keep you up to date in your field.

Existing User

New to Read

Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis

Discussion

Related Papers

Want full text access to this paper?

Read

Search Tips